FDA Expands Label for AZN’s Cancer Drug Calquence ... 498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in ...
Disc Medicine, Inc. will hold a conference call on January 21, 2025, at 8:00 am EST to discuss feedback from the FDA regarding its investigational drug, bitopertin, for treating Erythropoietic ...
The FDA has approved MediBeacon®'s TGFR system for noninvasive kidney function assessment, targeting both normal and impaired renal patients. INNOVATE Corp. announced the FDA approval of the ...
Amgen AMGN announced that the FDA has approved its KRAS inhibitor ... 498.3% and +673.0%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity ...
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
The company expects to regain compliance with Nasdaq Listing Rule 5250(c)(1), which ... by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated ...
(RTTNews) - AstraZeneca (AZN), on Friday, announced that the FDA has approved CALQUENCE in ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...
FDA Okays AstraZeneca And Daiichi's Datroway For Metastatic HR-Positive, HER2-Negative Breast Cancer
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds ...
Currently, Amgen's stock is trading at $272.83, up 1.26 percent on the Nasdaq. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those ...
FDA’s Priority Tag to AZN/Daiichi’s Dato ... Here’s how the eight major stocks performed in the previous five trading sessions. Image Source: Zacks Investment Research In the last five ...
Atara Biotherapeutics (ATRA) stock slips as company faces an FDA clinical hold after rejection of lead candidate Ebvallo.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback